Lee Gary K. 4
4 · Lyell Immunopharma, Inc. · Filed Feb 26, 2025
Insider Transaction Report
Form 4
Lee Gary K.
Chief Scientific Officer
Transactions
- Award
Common Stock
2025-02-10+112,500→ 176,696 total - Award
Option (right to buy)
2025-02-10+450,000→ 450,000 totalExercise: $0.55Exp: 2035-02-09→ Common Stock (450,000 underlying) - Award
Option (right to buy)
2025-02-10+56,250→ 56,250 totalExercise: $0.55Exp: 2035-02-09→ Common Stock (56,250 underlying)
Footnotes (4)
- [F1]12.5% of the total number of restricted stock units will vest on August 9, 2025, and thereafter an additional 1/16th of the total number of restricted stock units will vest quarterly thereafter, subject to the reporting person providing service through the applicable vesting date.
- [F2]Includes 7,800 shares acquired on May 17, 2024 and 3,696 shares acquired on November 18, 2024 under the Issuer's 2021 Employee Stock Purchase Plan.
- [F3]12.5% of the option shares will vest on August 9, 2025, with the remaining option shares to vest in equal monthly installments over the following forty-two months, subject to the reporting person providing service through the applicable vesting date.
- [F4]The reported transaction involved the reporting person's receipt of a grant of performance-based options, subject to vesting upon the achievement of specified performance criteria.